Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.

AIDS (London, England) - 21 Oct 2004

Fikkert Valery, Hombrouck Anneleen, Van Remoortel Barbara, De Maeyer Marc, Pannecouque Christophe, De Clercq Erik, Debyser Zeger, Witvrouw Myriam

Abstract excerpt

OBJECTIVES: Study of HIV-1 resistance development to the diketo analogue S-1360, the first HIV-1 integrase strand transfer inhibitor that has entered clinical development. DESIGN: HIV-1(IIIB) was passaged in cell culture in the presence of increasing concentrations of S-1360 (IIIB/S-1360(res)). M...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Clone Cells
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to HIV Infections

Share to HIV Integrase

Share to Triazoles

Share to Virus Replication

Source

Identifiers

PMID: 15577623
DOI: 10.1097/00002030-200410210-00006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-15577623-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.PMID 15577623Read ↗

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.Semantic proximity Read ↗

Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.Semantic proximity Read ↗

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.Semantic proximity Read ↗

Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.Semantic proximity Read ↗

The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.Semantic proximity Read ↗

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.Semantic proximity Read ↗

Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance SubstitutionsSemantic proximity Read ↗

Tenofovir resistance and resensitization.Semantic proximity Read ↗

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor DolutegravirSemantic proximity Read ↗

In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.Semantic proximity Read ↗

Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.Semantic proximity Read ↗

Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.